Steve Chung's (@stephenchung16) lab at @UTSWNews. Div. of Heme/Onc, Dept. of Internal Medicine. We study hematopoiesis, bone marrow failure, and leukemia.
Honored to contribute to this study by @SJMorrison_ and team. In patients undergoing allogeneic transplantation and receiving post-transplant cytoxan, the use of non-selective β-blockers may significantly delay engraftment and worsen survival. https://t.co/p8ktcsP7Sj
Our data suggest a simple peri-transplant change to β1-selective inhibitors (Carvedilol->Metoprolol) could mitigate this effect. Our findings were consistent @utswcancer and @VUMChealth, but validation at other centers promises to identify patients for whom this is most relevant.
I am honored to be a co-first author of our latest publication in @CD_AACR! This collaboration between @VUMC_Cancer and @UTSWMedCenter reveals how non-selective β-blockers impair hematopoietic regeneration after HCT. Our findings highlight the critical role of β-adrenergic signaling in recovery, offering actionable insights to improve outcomes for patients undergoing HCT. Excited to contribute to this impactful work with an incredible team!
@SJMorrison_@StephenChung16@huwenhuo@madanatyazan@DrAdetolaKassim
Non-selective b adrenergic receptor inhibitors impair hematopoietic regeneration in mice and humans after hematopoietic cell transplants https://t.co/7lBxqeTEE4
ONLINE NOW @CD_AACR: CRI scientists link hematopoietic cell transplant deaths to beta-blocker use. Research from @SJMorrison_, @StephenChung16 & @AshKishtagari shows nerve signaling needed for regeneration may be impaired by meds. #relentlessdiscovery https://t.co/03QwHl0x3Z
Congrats to Jinsuke Nishino, @StephenChung16 , @AshKishtagari, @huwenhuo on paper in Cancer Discovery today: use of non-selective b blockers impairs engraftment after allo hematopoietic cell transplants involving post-transplant chemo for GVHD prophylaxis
https://t.co/XqGyg2Qim7
For answers to these questions and more, please come to @BenrKroger‘s oral abstract (#347) today at 5:00 PM in Ballroom 20CD (San Diego Convention Center)
#ASH24@ASH_hematology#ASHTrainee @utsw_mstp @utswHemeOnc
Why do patients with germline mutations in DDX41 who develop MDS or AML have such indolent disease? How do somatic DDX41 mutations cause disease when present at very low levels? What are the role of other cooperating mutations? How does transplant work in these patients?
Congrats to @yuanyuanji7766 on a well-deserved Abstract Achievement Award at #ASH23 for her work linking genetics to dependence on regulated protein synthesis in LSCs. @utswcancer
Celebrating two new junior lab members, Raquel Felicity Carlsgaard and Townes Kroger. Congrats to proud Dad @CarlsgaardPeter and soon to be Dad @BenrKroger !!
Today’s first presenter at our WIPs is Ben Kroger, from @SChung_Lab. He delivered a great talk on hematopoietic stem cells to identify molecular mechanisms that drive the myelodysplastic syndromes!
Overwhelmed by the wealth of data on clonal hematopoiesis shown @ #ASH2022 ? Want to discuss some of the most interesting posters with the authors & colleagues interested in CHIP? Join our virtual poster walk tomorrow at 10AM CST / 5PM CET https://t.co/T8fvtkRwKA @ASH_hematology
Congrats to @BenrKroger and @TobyPThomas on their Abstract Acheivement awards #ASH2022. Come learn about a new MDS MRD assay and link between Clonal Hematopoiesis and Heart Failure at posters #4417 #3867, also featuring work from @yuanyuanji7766, @neslikalkan1, and @albertJWSon.
Our newest publication showing that pediatric AML can be classified into proteomic-signatures which are associated with both favorable or unfavorable prognosis is now online in Haematologica! Thanks to all who have contributed! @Haematologica
https://t.co/yTvyJWFYxA